These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19119291)

  • 21. Attitudes towards priority-setting and rationing in healthcare -- an exploratory survey of Swedish medical students.
    Omar F; Tinghög G; Tinghög P; Carlsson P
    Scand J Public Health; 2009 Mar; 37(2):122-30. PubMed ID: 19141543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decentralized health care priority-setting in Tanzania: evaluating against the accountability for reasonableness framework.
    Maluka S; Kamuzora P; San Sebastiån M; Byskov J; Olsen ØE; Shayo E; Ndawi B; Hurtig AK
    Soc Sci Med; 2010 Aug; 71(4):751-9. PubMed ID: 20554365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS and hospital priority setting: a qualitative case study and evaluation.
    Bell JA; Hyland S; DePellegrin T; Upshur RE; Bernstein M; Martin DK
    BMC Health Serv Res; 2004 Dec; 4(1):36. PubMed ID: 15606924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethics and economics: does programme budgeting and marginal analysis contribute to fair priority setting?
    Gibson J; Mitton C; Martin D; Donaldson C; Singer P
    J Health Serv Res Policy; 2006 Jan; 11(1):32-7. PubMed ID: 16378530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What do hospital decision-makers in Ontario, Canada, have to say about the fairness of priority setting in their institutions?
    Reeleder D; Martin DK; Keresztes C; Singer PA
    BMC Health Serv Res; 2005 Jan; 5(1):8. PubMed ID: 15663792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What reasons do those with practical experience use in deciding on priorities for healthcare resources? A qualitative study.
    Hasman A; McIntosh E; Hope T
    J Med Ethics; 2008 Sep; 34(9):658-63. PubMed ID: 18757635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herceptin, Pharmac and the New Zealand District Health Boards: keeping abreast of the Code of Health and Disability Services Consumers' Rights?
    Graham K
    J Law Med; 2008 Aug; 16(1):103-8. PubMed ID: 18807798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ethical choices in medically futile treatment].
    Miljeteig I; Johansson KA; Norheim OF
    Tidsskr Nor Laegeforen; 2008 Oct; 128(19):2185-9. PubMed ID: 18846142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Describing practices of priority setting and resource allocation in publicly funded health care systems of high-income countries.
    Seixas BV; Regier DA; Bryan S; Mitton C
    BMC Health Serv Res; 2021 Jan; 21(1):90. PubMed ID: 33499854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How much will Herceptin really cost? Balancing local and national priorities is not new.
    Dillon A; Littlejohns P
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158393
    [No Abstract]   [Full Text] [Related]  

  • 39. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
    Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethically acceptable prioritisation of childless couples and treatment rationing: "accountability for reasonableness".
    Lindström H; Waldau S
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):176-86. PubMed ID: 18417271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.